Louise Emmett, MD, presented “PSMA in Metastatic Prostate Cancer: Imaging as Biomarker” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Emmett, Louise “PSMA in Metastatic Prostate Cancer: Imaging as Biomarker.” September 22, 2023. Accessed Aug 2024. https://grandroundsinurology.com/psma-in-metastatic-prostate-cancer-imaging-as-biomarker/
PSMA in Metastatic Prostate Cancer: Imaging as Biomarker – Summary
Louise Emmett, MD, addresses prostate-specific membrane antigen (PSMA) in metastatic prostate cancer, focusing on imaging as a biomarker. She emphasizes the critical advancements in PSMA imaging and its transformative impact on the diagnosis and management of metastatic prostate cancer.
Emmett underscores how PSMA-targeted imaging agents, such as PSMA PET/CT, have revolutionized the visualization of prostate cancer metastases with high sensitivity and specificity. This imaging modality allows for the precise localization of metastatic lesions, significantly improving the staging and restaging of the disease. Recent studies demonstrate that PSMA PET/CT can identify patients who are likely to benefit from targeted therapies, thereby optimizing treatment outcomes and minimizing unnecessary toxicity.
Emmett also explores the integration of PSMA imaging with other diagnostic and therapeutic strategies. She highlights the synergistic potential when combined with conventional imaging techniques, molecular diagnostics, and emerging treatments.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Professor Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent's Hospital Sydney. She has been instrumental in developing the radiopharmacy initiative on the St Vincent's Campus and has introduced multiple new radioisotopes for clinical and research purposes. The St Vincent's Theranostics Department is highly published in both PET imaging and radionuclide therapy. Louise is heavily involved in multi-site multidisciplinary trials run across Australia, in addition to undertaking early phase clinical trials on the St Vincent's Campus. She believes in the power of clinical research to optimise treatments and improve lives.
Louise completed medical school at Auckland University (1992), New Zealand and received her FRACP qualification in Sydney, Australia (1999). She undertook a specialty fellowship in Nuclear Cardiology at the University Health Network in Toronto (2000), and completed a Doctorate of Medicine in Nuclear Cardiology through Auckland University in 2014. Since commencing work at St Vincent's Hospital in 2012, her focus has shifted to Theranostics. Happily this shift in focus (mid-life crisis) coincided with the first publication of PSMA imaging in a mouse. Louise is a clinical professor with the University of New South Wales. She has published over 80 original papers in peer reviewed journals in the last 10 years, has received a number of grants for clinical research and has presented at numerous national and international meetings.
